A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)

Trial Profile

A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms AIM
  • Most Recent Events

    • 29 Mar 2018 Results assessing efficacy of venetoclax in combination with Ibrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma, were published in the New England Journal of Medicine.
    • 06 Jun 2017 Results (n=18, Data cut off Jan 11 2017), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Sep 2016 Status changed from recruiting to active, no longer recruiting as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top